A novel multivalent OspA vaccine against lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi Sensu Lato

Clinical and Vaccine Immunology

Volumn 21, Issue 11, 2014, Pages 1490-1499

  Wressnigg, Nina ^a   Noel Barrett, P ^a   Pöllabauer, Eva Maria ^a   O'Rourke, Maria ^a   Portsmouth, Daniel ^a   Schwendinger, Michael G ^a   Crowe, Brian A ^a   Livey, Ian ^a   Dvorak, Thomas ^a   Schmitt, Bernhard ^b   Zeitlinger, Markus ^c   Kollaritsch, Herwig ^c   Esen, Meral ^d   Kremsner, Peter G ^d   Jelinek, Tomas ^e   Aschoff, Roland ^f   Weisser, Roland ^g   Naudts, Ingomar F K ^h   Aichingera, Gerald ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Pain Clinic Mainz   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Berlin Center for Travel and Tropical Medicine   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g Hautarztpraxis Cutanis   (Germany)

^h Private Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; OUTER SURFACE PROTEIN A; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; BACTERIAL VACCINE; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPOPROTEIN; MEMBRANE ANTIGEN; OUTER MEMBRANE PROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; AUSTRIA; BORRELIA BURGDORFERI; BORRELIA BURGDORFERI SENSU LATO; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GERMANY; GROUPS BY AGE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYME DISEASE; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; SWELLING; TREATMENT DURATION; VACCINATION; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ALUM COMPOUNDS; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI GROUP; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE; MALE; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84914670631     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00406-14     Document Type: Article

References (39)

1. Stanek G, Wormser GP, Gray J, Strle F. 2012. Lyme borreliosis. Lancet 379:461-473. http://dx.doi.org/10.1016/S0140-6736(11)60103-7.
2. Steere AC, Livey I. 2012. Lyme disease vaccines, p 1122-1132. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 6th ed, Elsevier, Philadelphia, PA.
3. Centers for Disease Control and Prevention (CDC). 2013. Notice to readers: final 2012 reports of nationally notifiable infectious diseases. MMWR Morb. Mortal. Wkly. Rep. 62:669-682.
4. Kuehn BM. 2013. CDC estimates 300,000 U.S. cases of Lyme disease annually. JAMA 310:1110. http://dx.doi.org/10.1001/jama.2013.278331.
5. Lindgren E, Jaenson TGT. 2006. Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. World Health Organization Regional Office for Europe, Copenhagen, Denmark. http://www.euro.who.int/document/E89522.pdf.
6. Plotkin SA. 2011. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52(Suppl 3):s271-s275. http://dx.doi.org/10.1093/cid/ciq119.
7. Steere AC, Angelis SM. 2006. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 54:3079-3086. http://dx.doi.org/10.1002/art.22131.
8. Hanrahan JP, Benach JL, Coleman JL, Bosler EM, Morse DL, Cameron DJ, Edelman R, Kaslow RA. 1984. Incidence and cumulative frequency of endemic Lyme disease in a community. J. Infect. Dis. 150:489-496. http: //dx.doi.org/10.1093/infdis/150.4.489.
9. Lastavica CC, Wilson ML, Berardi VP, Spielman A, Deblinger RD. 1989. Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts. N. Engl. J. Med. 320:133-137. http://dx.doi.org/10.1056 /NEJM198901193200301.
10. Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. 1986. Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population. J. Infect. Dis. 154:295-300. http://dx.doi.org/10.1093/infdis/154.2.295.
11. Steere AC, Sikand VK, Schoen RT, Nowakowski J. 2003. Asymptomatic infection with Borrelia burgdorferi. Clin. Infect. Dis. 37:528-532. http://dx.doi.org/10.1086/376914.
12. Fahrer H, van der Linden SM, Sauvain MJ, Gern L, Zhioua E, Aeschlimann A. 1991. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J. Infect. Dis. 163:305-310. http://dx.doi.org/10.1093/infdis/163.2.305.
13. Gustafson R, Svenungsson B, Gardulf A, Stiernstedt G, Forsgren M. 1990. Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population. Scand. J. Infect. Dis. 22:297-306. http://dx.doi .org/10.3109/00365549009027051.
14. Zhioua E, Gern L, Aeschlimann A, Sauvain MJ, Van der Linden S, Fahrer H. 1998. Longitudinal study of Lyme borreliosis in a high risk population in Switzerland. Parasite 5:383-386.
15. Nadelman RB, Wormser GP. 2007. Reinfection in patients with Lyme disease. Clin. Infect. Dis. 45: 1032-1038. http://dx.doi.org/10.1086 /521256.
16. Nadelman RB, Hanincová K, Mukherjee P, Liveris D, Nowakowski J, McKenna D, Brisson D, Cooper D, Bittker S, Madison G, Holmgren D, Schwartz I, Wormser GP. 2012. Differentiation of reinfection from relapse in recurrent Lyme disease. N. Engl. J. Med. 367:1883-1890. http://dx.doi.org/10.1056/NEJMoa1114362.
17. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339:209-215.
18. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE. 1998. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339:216-222.
19. Steere AC, Drouin EE, Glickstein LJ. 2011. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin. Infect. Dis. 52(Suppl 3):s259-s265. http://dx.doi.org/10.1093/cid/ciq117.
20. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, Field JA, Steere AC, Huber BT. 1998. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281: 703-706. http://dx.doi.org/10.1126/science.281.5377.703.
21. Poland GA. 2011. Vaccines against Lyme disease: what happened and what lessons can we learn? Clin. Infect. Dis. 52(Suppl 3):s253-s258. http: //dx.doi.org/10.1093/cid/ciq116.
22. Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN. 2013. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect. Dis. 13:680-689. http://dx.doi.org/10.1016/S1473-3099(13)70110-5.
23. Livey I, O'Rourke M, Traweger A, Savidis-Dacho H, Crowe BA, Barrett PN, Yang X, Dunn JJ, Luft BJ. 2011. A new approach to a Lyme disease vaccine. Clin. Infect. Dis. 52(Suppl 3):s266-s270. http://dx.doi.org/10 .1093/cid/ciq118.
24. U.S. FDA. 2011. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
25. Schwan TG. 2003. Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi. Biochem. Soc. Trans. 31: 108-112.
26. Benach JL, Coleman JL, Garcia-Monco JC, Deponte PC. 1988. Biological activity of Borrelia burgdorferi antigens. Ann. N. Y. Acad. Sci. 539:115-125. http://dx.doi.org/10.1111/j.1749-6632.1988.tb31845.x.
27. Schoen RT, Meurice F, Brunet CM, Cretella S, Krause DS, Craft JE, Fikrig E. 1995. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J. Infect. Dis. 172:1324-1329. http://dx.doi.org/10.1093/infdis/172.5.1324.
28. Fikrig E, Huguenel ED, Berland R, Rahn DW, Hardin JA, Flavell RA. 1992. Serologic diagnosis of Lyme disease using recombinant outer surface proteins A and B and flagellin. J. Infect. Dis. 165:1127-1132. http://dx.doi .org/10.1093/infdis/165.6.1127.
29. Schoen RT, Sikand VK, Caldwell MC, Van Hoecke C, Gillet M, Buscarino C, Parenti DL. 2000. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin. Ther. 22:315-325. http://dx .doi.org/10.1016/S0149-2918(00)80035-1.
30. Schoen RT, Deshefy-Longhi T, Van Hoecke C, Buscarino C, Fikrig E. 2003. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clin. Ther. 25:210-224. http://dx.doi.org/10.1016/S0149-2918(03)90027-0.
31. Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, Lebacq E, Lobet Y, Voet P. 1996. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620-1626. http://dx .doi.org/10.1016/S0264-410X(96)00146-6.
32. Van Hoecke C, Fu D, De Grave D, Voet P, Lebacq E. 1998. Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12. Vaccine 16: 1688 -1692. http://dx.doi.org/10.1016/S0264 -410X(98)00052-8.
33. Van Hoecke C, Lebacq E, Beran J, Parenti D. 1999. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin. Infect. Dis. 28:1260-1264. http://dx.doi.org/10.1086/514779.
34. van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. 2012. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 30:6127-6135. http://dx.doi.org/10.1016/j.vaccine.2012.07.077.
35. Klein J. 1982. Immunology: the science of self/nonself discrimination, p 507-574. John Wiley & Sons, New York, NY.
36. Siegrist C. 2008. Vaccine immunology, p 17-36. In Plotkin S, Orenstein W, Offit P (ed), Vaccines, 5th ed, Elsevier, Philadelphia, PA.
37. Heyzer-Williams M, Okitsu S, Wang N, Heyzer-Williams L. 2012. Molecular programming of B cell memory. Nat. Rev. Immunol. 12:24-34. http://dx.doi.org/10.1038/nri3128.
38. Pelletier N, Heyzer-Williams LJ, Wong KA, Urich E, Fazilleau N, McHeyzer-Williams MG. 2010. Plasma cells negatively regulate the follicular helper T cell program. Nat. Immunol. 11:1110-1118. http://dx.doi .org/10.1038/ni.1954.
39. Schwendinger MG, O'Rourke M, Traweger A, Savidis-Dacho H, Pilz A, Portsmouth D, Livey I, Barrett PN, Crowe BA. 2013. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model. PLoS One 8:e79022. http://dx.doi.org/10.1371/journal.pone.0079022.